Collegium Pharmaceutical Inc Revenue Growth Rates (COLL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Collegium Pharmaceutical Inc   (NASDAQ: COLL)
 

COLL's Revenue Growth by Quarter and Year

Collegium Pharmaceutical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

COLL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 199.88
1st Quarter March 137.25
FY 337.13

COLLs Annual Revenue
Collegium Pharmaceutical Inc 's Revenue in the fiscal year 2025 $ 558.26 millions
Collegium Pharmaceutical Inc 's Revenue in the fiscal year 2024 $ 465.34 millions
Collegium Pharmaceutical Inc 's Revenue in the fiscal year 2023 $ 420.17 millions
Collegium Pharmaceutical Inc 's Revenue in the fiscal year 2022 $ 327.68 millions
Collegium Pharmaceutical Inc 's Revenue in the fiscal year 2021 $ 403.12 millions




COLL Revenue second quarter 2026 Y/Y Growth Comment
Collegium Pharmaceutical Inc reported Revenue growth of 6.67% year on year in the second quarter 2026, to $ 199.88 millions, this is lower than Collegium Pharmaceutical Inc 's recent average Revenue surge of 275.78%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 113 other companies have achieved higher Revenue growth. While Collegium Pharmaceutical Inc ' s Revenue increase of 6.67% ranks overall at the positon no. 2070 in the second quarter 2026.


COLL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 12.92 % 21.5 % 15.53 %
3rd Quarter September - 31.73 % 16.49 % 7.32 %
2nd Quarter June 6.67 % 29.4 % 7.4 % -30.76 %
1st Quarter March -22.6 % 22.75 % -0.21 % 21.65 %
FY   - 23.7 % 11.38 % -

Financial Statements
Collegium Pharmaceutical Inc 's second quarter 2026 Revenue $ 199.88 millions COLL's Income Statement
Collegium Pharmaceutical Inc 's second quarter 2025 Revenue $ 187.38 millions Quarterly COLL's Income Statement


COLL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -1.78 % 14.59 % 9.86 %
3rd Quarter September - 11.63 % 9.65 % 1.1 %
2nd Quarter June 45.63 % 5.67 % 0.24 % -6.87 %
1st Quarter March -33.2 % -2.54 % -3.53 % 11.69 %
FY (Year on Year)   - 23.7 % 11.38 % -


Back to COLL Growth rate Comparisons >> Back to COLL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #114
Healthcare Sector #310
Overall #2070

Revenue Y/Y Growth Statistics
High Average Low
2835.04 % 275.78 % -30.76 %
(Jun 30 2018)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #114
Healthcare Sector #310
Overall #2070
Revenue Y/Y Growth Statistics
High Average Low
2835.04 % 275.78 % -30.76 %
(Jun 30 2018)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Collegium Pharmaceutical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
490.6 % 33.44 % -49.76 %
(Mar 31 2018)  


COLL's II. Quarter Q/Q Revenue Comment
Collegium Pharmaceutical Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 45.63%, to $ 199.88 millions, from $137.25 millions in the first quarter.
COLL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Collegium Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 264.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #70
Overall #264
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #70
Overall #264
Revenue Q/Q Growth Statistics
High Average Low
490.6 % 33.44 % -49.76 %
(Mar 31 2018)  


COLL's II. Quarter Q/Q Revenue Comment
Collegium Pharmaceutical Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 45.63%, to $ 199.88 millions, from $137.25 millions in the first quarter.
COLL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Collegium Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 264.


Collegium Pharmaceutical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 751.74 $ 739.25 $ 779.33 $ 755.83 $ 705.45
Y / Y Revenue Growth (TTM) 6.56 % 11.52 % 23.7 % 26.43 % 22.62 %
Year on Year Revenue Growth Overall Ranking # 976 # 758 # 668 # 1930 # 2726
Seqeuential Revenue Change (TTM) 1.69 % -5.14 % 3.11 % 7.14 % 6.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 2024 # 1593 # 1247 # 1122 # 1806


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Collegium Pharmaceutical Inc 's cumulative twelve months Revenue were $ 752 millions, company would post below average annual Revenue growth of 6.42% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Collegium Pharmaceutical Inc 's Revenue growth from the 137.25% growth in Mar 31 2026.

In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 758 to 976.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 192
Overall # 976

Revenue TTM Y/Y Growth Statistics
High Average Low
2043.68 %
 148.19 %
-5.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2024
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Collegium Pharmaceutical Inc 's cumulative twelve months Revenue were $ 752 millions, company would post below average annual Revenue growth of -5.17% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Collegium Pharmaceutical Inc 's Revenue growth from the 137.25% growth in Mar 31 2026.

In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 758 to 976.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 192
Overall # 976

Revenue TTM Y/Y Growth Statistics
High Average Low
2043.68 %
148.19 %
-5.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2024




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
COLL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions


About Collegium Pharmaceutical Inc Revenue Growth Rates (COLL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Collegium Pharmaceutical Inc (CIK 1267565).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-053851
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Collegium Pharmaceutical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.